Efficacy and safety of an amino acid jelly containing coenzyme Q10 and l-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01)
- 754 Downloads
Cancer-related fatigue (CRF) is one of the most common symptoms reported by cancer patients. This randomized trial investigated the efficacy of the amino acid jelly Inner Power® (IP), a semi-solid, orally administrable dietary supplement containing coenzyme Q10 and l-carnitine, in controlling CRF in breast cancer patients in Japan.
Breast cancer patients with CRF undergoing chemotherapy were randomly assigned to receive IP once daily or regular care for 21 days. The primary endpoint was the change in the worst level of fatigue during the past 24 h (Brief Fatigue Inventory [BFI] item 3 score) from day 1 (baseline) to day 22. Secondary endpoints were change in global fatigue score (GFS; the average of all BFI items), anxiety and depression assessed by the Hospital Anxiety and Depression Scale (HADS), quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Breast Cancer-Specific QLQ (EORTC QLQ-BR23), and adverse events.
Fifty-nine patients were enrolled in the study, of whom 57 were included in the efficacy analysis. Median patient age was 50 years. Changes in the worst level of fatigue, GFS, and current feeling of fatigue were significantly different between the intervention and control groups, whereas the change in the average feeling of fatigue was not significantly different between groups. HADS, EORTC QLQ-C30, and EORTC QLQ-BR23 scores were not significantly different between the two groups. No severe adverse events were observed.
IP may control moderate-severe CRF in breast cancer patients.
The registration number of this study in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) is UMIN000008646.
KeywordsCancer-related fatigue Chemotherapy-induced fatigue Supplement Quality of life Complementary and alternative medicine
Conflict of interest
This was a joint study conducted by The University of Tokyo and Otsuka Pharmaceutical Factory Incorporated. Financial resources and Inner Power® were provided by Otsuka Pharmaceutical Factory Incorporated. The funding source had no influence on the study outcomes, and the authors were free to interpret the data according to a strict scientific rationale. The authors have no other conflicts of interest to disclose. The authors have full control of all primary data and agree to allow the journal to review their data if requested.
- 1.Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C (2000) NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 14:151–161Google Scholar
- 9.Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31:3076–3082PubMedCrossRefGoogle Scholar
- 11.Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ, Suh JJ, Griffin PC, Johnson DB, Ali A, Silberstein PT, Duane SF, Loprinzi CL (2010) Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central cancer treatment group NCCTG-N05C7 trial. J Clin Oncol 28:3673–3679PubMedPubMedCentralCrossRefGoogle Scholar
- 14.Jean-Pierre P, Morrow GR, Roscoe JA, Heckler C, Mohile S, Janelsins M, Peppone L, Hemstad A, Esparaz BT, Hopkins JO (2010) A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 116:3513–3520PubMedPubMedCentralCrossRefGoogle Scholar
- 18.Higashiguchi T, Futamura A, Ito A (2010) Effect of a complementary nutrition diet for improving clinical condition and function in terminal cancer patients: a controlled clinical trial. JJSMN 44:157–169Google Scholar
- 21.Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L, Lamonica G, Dessi M, Spiga C, Astara G, Maccio A, Mantovani G (2006) Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 22:136–145PubMedCrossRefGoogle Scholar
- 25.Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, Schnipper HH, Lacchetti C, Ligibel JA, Lyman GH, Ogaily MS, Pirl WF, Jacobsen PB (2014) Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 32:1840–1850PubMedPubMedCentralCrossRefGoogle Scholar
- 31.Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osaba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRefGoogle Scholar
- 33.Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK (1996) The European organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14:2756–2768PubMedGoogle Scholar
- 34.Okamoto T, Shimozuma K, Katsumata N, Koike M, Hisashige A, Tanaka K, Ohsumi S, Saito M, Shikama N, Mitsumori M, Yamauchi C, Watanabe T (2003) Measuring quality of life in patients with breast cancer: a systematic review of reliable and valid instruments available in Japan. Breast Cancer (Tokyo) 10:204–213CrossRefGoogle Scholar
- 36.World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects 2008. http://www.wma.net/en/30publications/10policies/b3/ Accessed: 3 Dec 2014
- 37.The Ethical Guidelines for Clinical Research (Ministry of Labor, Health, and Welfare of Japan). http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/rinsyo/dl/shishin.pdf. Accessed: 3 Dec 2014
- 39.Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, Naughton MJ, Vitolins MZ, Lively MO, Shaw EG, Wake Forest University Community Clinical Oncology Program Research B (2013) A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol 11:31–42PubMedPubMedCentralGoogle Scholar
- 40.Cruciani RA, Zhang JJ, Manola J, Cella D, Ansari B, Fisch MJ (2012) l-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol 30:3864–3869PubMedPubMedCentralCrossRefGoogle Scholar
- 41.Patient-Reported Outcomes (Society for Clinical Data Management’s Good Clinical Data Management Practices). http://www.scdm.org/ Accessed: 3 Dec